In partnership with our network partners, together, we have shared research on real-world treatment patterns in breast and non-small cell lung cancer.
By Antoinette Cummins
Fresh off a $68 million funding round, Syapse is moving quickly to expand its network of partnerships with life sciences companies, health systems, molecular laboratories, and regulators.
“We’re right in the middle of growth mode right now,” CEO Ken Tarkoff said of the 13-year-old company. The San Francisco-based maker of software to support precision oncology care and drug discovery also raised $30 million in a round that closed in May 2020.
By Courtney Bennett
San Francisco, CA - June 3, 2021 - Syapse®, a leading real-word evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing real world care, today announced the publication of five abstracts at the American Society for Clinical Oncology (ASCO) 2021 Annual Meeting, being held virtually June 4 – 8. Each study util…
Washington, D.C.(May 19, 2021) – Five real-world data (RWD) and analytics organizations today announced an industry coalition dedicated to advancing the use of real-world evidence (RWE) to support regulatory decisions. Founding members of the RWE Alliance are Aetion, Flatiron Health, IQVIA, Syapse, and Tempus.
The RWE Alliance intends to en…
San Francisco, California – April 6, 2021 – Syapse®, a leading real-world evidence company accelerating the delivery of precision medicine through the Syapse Learning Health NetworkTM, today announced that the findings of a peer-reviewed study were published in JCO Clinical Cancer Informatics (JCO-CCI), an American Society of Clinical Oncology (ASC…
February 24, 2021
In this dialogue, Dr. Thomas Brown, chief medical officer at Syapse, interviews Dr. Leroy (Lee) Hood, co-founder of Institute for Systems Biology (ISB). A world-renowned scientist and recipient of the National Medal of Science in 2011, Dr. Leroy Hood co-founded the Institute for Systems Biology (ISB) in 2000 and served as its first President from 2000-2017. In 2016, ISB affiliated with Providence St. Joseph Health (PSJH) and Dr. Hood became PSJH’s Senior Vice President and Chief Science Officer. Dr. Hood has played a role in founding 15 biotechnology companies including Amgen, Applied Biosystems, Arivale, and Nanostring. He has co-authored textbooks in biochemistry, immunology, molecular biology, genetics, and systems biology.
June 10, 2021
During this webinar, we highlight strategic approaches you, and your organization, should consider as you invest in RWD to best capture the comprehensive patient journey needed to answer your most challenging questions, or seek to validate real-world endpoints.
If you’d like to learn more about Syapse, tell us a little about yourself and we will reach out as soon as possible.